KEY SPEAKERS INCLUDE:

• Michael Krams, MD, Global Head, Quantitative Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson
• Vladimir Anisimov, Senior Strategic Biostatistics Director, Quintiles
• Roger Lewis, MD, PhD, Senior Medical Scientist, Berry Consultants
• Loic Darchy, Head of Statistical Methodology Group, Sanofi R&D
• Lila Di Scala, Senior Statistical Scientist, Roche
• Pantelis Viachos, Principle Biostatistician, Strategic Consulting, Cytel Corporation
• Sue Todd, Professor of Medical Statistics, University of Reading
• Frank Fleischer, Principal Statistician, Boehringer-Ingelheim
• Christopher Jennison, Professor of Statistics, University of Bath
• Graeme Archer, Statistics Director, GlaxoSmithKline

WHY ATTEND THIS EVENT:

• Learn from Michael Krams how to create an environment where adaptive designs can become the norm
• The only conference in Europe to focus specifically on adaptive designs in clinical trials
• Benefit from the first-hand experiences of speakers whose organisations have recently made breakthroughs in adaptive designs
• Hear from Vladimir Anisimov the very latest on predicative analytical techniques for increasing efficiency of drug development
• Discover at our post conference workshop how FACT software that supports the ever-increasing complexity of adaptive clinical trials works, hosted by Tom Parke of Tessella

PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS

Wednesday 26th March 2014 | Holiday Inn Regents Park, London, UK

Workshop A: Simulating Clinical Trials using the FACTS software package: Why simulate clinical trials, how to simulate clinical trials and the difference it will make
8.30am – 1.00pm
Workshop Leader: Tom Parke, Head of Clinical Trial Solutions, Tessella Ltd

Workshop B: Identifying and Exploiting Opportunities for Efficiency in Clinical Trial Design: An Interactive Adaptive Design Workshop
1.00pm - 5.00pm
Workshop Leader: Professor Roger J. Lewis, MD, PhD, Senior Medical Scientist, Berry Consultants

www.adaptivedesigns.co.uk
BOOK BY 29TH NOVEMBER AND SAVE £300 / BOOK BY 31ST JANUARY AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
Case Study: Re-engineering Phase 2

The Collaborative Adaptive Clinical Trial Design Process: Biomarker-adaptive designs in oncology:

- Building infrastructure to apply broadly in a scalable fashion
- Creating an environment where adaptive designs can become the norm
- The execution and how to ensure this happens

Michael Krams, MD, Global Head, Quantitative Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson

Application of Adaptive Design in PPP’s

- Use of adaptive design to characterize exposure-response relationship
- Addressing the challenge of adaptive dose-allocation under several constraints
- Simulation of operating characteristics to inform design choice

Baldur Magnusson, Senior Principal Statistical Scientist, Novartis International AG

Designing a trial to find the minimum inhibitory concentration of an anti-infective drug

- Benefits of simulations are well known and often referenced; however, many companies still do not perform them
- With the main advocates of simulations in statistics departments, how can we engage people from other departments in the process?
- Case studies to show what has and has not worked well

Jürgen Hummel, Associate Statistical Science Director, PPD

The Collaborative Adaptive Clinical Trial Design Process: Teamwork Informed by Simulation

- Adaptive trial designs leverage the incoming stream of new information that arises during clinical trial conduct to improve the statistical efficiency, validity, and safety of a clinical investigation;
- Identifying the most powerful ways to use this incoming information stream is the “art” of adaptive design and requires, in each case, a detailed and quantitative understanding of the threats to trial validity and success
- The best adaptive clinical trial designs are created in a collaborative, interactive process involving statisticians, clinical domain experts, and trial implementers that are informed by detailed trial simulations.

Roger Lewis, MD, PhD, Senior Medical Scientist, Berry Consultants

Adaptive Designs: Barriers for routine use and how to overcome them

- The best adaptive clinical trial designs are created in a collaborative, interactive process involving statisticians, clinical domain experts, and trial implementers that are informed by detailed trial simulations.

Surinder Bhatia, Principle Biostatistician, Quantitative Sciences, PPD

Simulations: Barriers for routine use and how to overcome them

- Benefits of simulations are well known and often referenced; however, many companies still do not perform them
- With the main advocates of simulations in statistics departments, how can we engage people from other departments in the process?
- Case studies to show what has and has not worked well

Jürgen Hummel, Associate Statistical Science Director, PPD

Advances in Methodology for Phase II/III Clinical Trials

- Recent developments in design
- Methods of analysis for phase II/III trials
- Examples of implementation

Sue Todd, Professor of Medical Statistics, University of Reading

Using simulation and Biomarkers to speed phase I - II development: A case study

- The Development Scenario
- Bayesian Modelling Overview
- Simulation Cases
- Selected Results
- Conclusions

Pantelis Vlachos, Principle Biostatistician, Strategic Consulting, Cytel Corporation

Biomarker-adaptive designs in oncology: can confirmatory studies tackle sub-population finding?

- Bio/immune-markers potentially predictive of treatment benefits
- Examples of threshold identification as well as an example of an already dichotomized marker and the subsequent decision on the testing hierarchy
- Strategic concerns and implications of including a biomarker-defined sub-population in a confirmatory study

Lilla Di Scala, Senior Statistical Scientist, Roche

Cytel sponsored panel discussion

Adaptive Designs: Barriers and the Future

- Critical appraisal of adaptive designs: where are the real gains?
- Is wider acceptance linked to how the methods fare in the public sector? To become common practice more people need to be using the approach – not just the pharmaceutical industry
- Has there been a collective “undue advocacy” of adaptive trials by proponents? Have we unintentionally created unrealistic expectations of improving outcomes and/or efficiencies?
- Will the adjective “adaptive” be dropped some day, as all trials will be adaptive (in one form or another)?
- How will trends toward modeled patients (physically and virtually) change the future of trials? Will we see trials without humans in our lifetimes?

Discussion Moderator:

Michael Krams, MD, Global Head, Quantitative Sciences, GlaxoSmithKline

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients accelerate the delivery of safe and effective therapeutics.

www.ppd.com

Sponsored by:

Cytel

Our mission at Cytel is to improve success rates in the development of drugs, biologics and medical devices. We do this by improving clinical trials through innovative application of statistical science with software based on state-of-the-art computational methods.

We are leaders in adaptive trial planning and implementation. Every adaptive design reviewed by regulators has been deemed acceptable and all 25 leading global biopharma companies rely on our technology in their clinical studies. www.cytel.com

Sponsored by:

Cytel

Our mission at Cytel is to improve success rates in the development of drugs, biologics and medical devices. We do this by improving clinical trials through innovative application of statistical science with software based on state-of-the-art computational methods.

We are leaders in adaptive trial planning and implementation. Every adaptive design reviewed by regulators has been deemed acceptable and all 25 leading global biopharma companies rely on our technology in their clinical studies. www.cytel.com

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients accelerate the delivery of safe and effective therapeutics.

www.ppd.com
09.00 Chairman’s Opening Remarks
Vladimir Anisimov, Senior Strategic Biostatistics Director, Quintiles

09.10 Revisiting the Biomarker Adaptive Threshold Design (BATD)
- Is there a need for a study extension?
  - The BATD design was recently proposed and assessed by the US National Cancer Institute
  - The present work used as a starting point their landmark publication in Journal National Cancer Institute, 2007
  - The limitations of the design will be discussed and naturally lead us to consider an extension to the BATD design; that extension consists of an extension phase focusing on the particular subset of interest as identified by the testing procedure underlying their approach (if any) when the initial study is statistically inconclusive.
  - Go/no go criteria for such an extension are discussed.
Loïc Darchy, Head of Statistical Methodology Group, Sanofi R&D

09.50 Designing an Adaptive Trial using a Combination Test for a Survival Endpoint
- A clinical trial with a survival endpoint and treatment selection
- Protecting the type I error rate in an adaptive design
- Problems in applying a combination test to survival data
- A new combination test for an adaptive design with survival data
  Christopher Jennison, Professor of Statistics, University of Bath

10.30 Morning Coffee

10.50 Predictive analytical techniques for modelling operational characteristics in clinical trials
- Main uncertainties and interactions between adaptive trial design, patient enrolment, randomization
- Modelling and adaptive adjustment of patient enrolment
- Predictive modelling operational characteristics (visits, events and associated costs)
- Optimization of different stages of drug development
  Prof. Dr. Vladimir Anisimov, Senior Strategic Biostatistics Director, Quintiles

11.30 Designing multi-arm multi-stage trials with a safety and an efficacy endpoint
- Multi-arm clinical trials that compare several treatments to a common control as an efficient means of making an informed decision about which treatment should be evaluated further in a confirmatory study
- The constraint that selection and formal testing should be based on a single efficacy endpoint, despite the fact that in practice, safety considerations will often play a central role in determining selection decisions
- Multi-arm, multi-stage design for a trial with an efficacy and a safety endpoint considering the situation where a minimal safety requirement is to be fulfilled and the treatment yielding the best combined safety and efficacy trade-off satisfying this constraint is selected for further testing
- Selections made at the first interim analysis while the whole trial is allowed to comprise of J analyses
  Lisa Hampson, MRC Career Development Award Fellow in Biostatistics, University of Lancaster

12.10 Networking Lunch

13.30 Cost-effectiveness of alternative designs in CV outcome studies
- Fundamentals of sequential and adaptive design
- Robust design of clinical trials
- Decision support using a monetary utility function
- A case-study will illustrate the ideas using simulated data
  Mats Kvarnström, Principal Statistician, AstraZeneca

14.10 Optimum Adaptive Design for Dose Finding in Early Clinical Trials
Incorporating PK Information
- Efficient and ethical dose allocation
- Population variability accounted for in optimum PK sampling times
- Dose finding targeted at desirable drug exposure
  Barbara Bogacka, Reader in Statistics, Queen Mary, University of London

14.50 Afternoon Tea

15.10 Flexible Designs in Phase I Pharmacokinetic Trials
- Basic concepts of Phase I PK trials
- Adaptive and flexible approaches to Phase I bioequivalence trials
- An evaluation of flexible designs vs pilot/main study approaches
  Frank Reither, Principal Statistician, Boehringer-Ingelheim

15.50 Adaptive elements in clinical pharmacology trials
- Adaptations in first in human trials
- Efficient planning of bioavailability and bioequivalence trials
- The role of pilot and feasibility trials in particular in academic research
  Arne Ring, Principal Statistician, University of Leicester

16.30 Chairman’s Closing Remarks and Close of Day Two
Workshop Leader:
Tom Parke, Head of Clinical Trial Solutions, Tessella Ltd

Overview of workshop:
The purpose of the workshop is twofold, firstly to introduce the art of simulating clinical trials, and illustrating the many advantages of doing it. Secondly simulation will be demonstrated using the FACTS software (as this will allow us to specify and run simulations very quickly and visibly) and thus the workshop will show some of the capabilities of the FACTS software and how it can be used in trial design.

Workshop Agenda:

8.30 Coffee & Registration

9.00 Introduction to trial simulation
  • The simulation process
  • The design using simulation process – art and science
  • Simulation and interaction with the project team

10.00 Worked example – phase 1 dose escalation using the New CRM method
  • Specifying scenarios
  • Conveying the design
  • Optimising the design

10.45 Coffee Break

11.00 Worked example – phase 2 dose finding design
  • Incremental design
  • Dose response modelling
  • Longitudinal modelling
  • Adaptive design

12.00 Extending the example and the simulation process
  • Using data from pharmacometrics
  • Optimising the design in the light of the whole development program

12.45 Final Discussion/Q&A

13.00 Close of workshop

About the workshop host
Tom has been working at Tessella for over fifteen years. In 1998 he had the great good fortune to work on Pfizer’s ASTIN Stroke trial managed by Dr Michael Krams and designed by Prof Don Berry and Dr Peter Mueller. This was a landmark trial that used Bayesian modelling to optimize the allocation of subjects to doses and decide when to stop the trial.

Tom has now helped implement numerous Bayesian, response adaptive, phase 2 dose finding trials, for a range of pharmaceutical companies across a range of indications. Building systems to support the running of the trials and integrate the adaptive algorithms with existing IVRS and EDC systems.

He is currently leading projects within Tessella to develop tools for the modelling and simulation of drug development including ‘FACTS’ the Fixed and Adaptive Clinical Trial Simulator, that is developed in partnership with Berry Consultants.
Overview of workshop:
Using trial examples provided by the workshop participants, the instructor will demonstrate the process of identifying opportunities for increasing clinical trial efficiency and minimizing the risk of a failed trial, by applying adaptive design principles. By using actual examples, modified to whatever extent is required by considerations of confidentiality, the focus will be on solving real challenges facing those working on the development of innovative pharmaceuticals, biologics, or medical devices. Logistical and implementation challenges associated with the proposed designs, and their solutions, will be discussed as well.

Workshop Agenda:

1.00 Coffee & Registration

1.30 Opening
   • Review of the "toolbox" of adaptive techniques that can commonly be applied
   • Advantages, challenges, and regulatory considerations in the choice of adaptive techniques to be considered
   • Evaluation and "stress testing" of proposed adaptive designs

2.00 Identification and Evaluation of Opportunities for Increasing Clinical Trial Efficiency
   • Interactive discussion of clinical trial examples provided by workshop participants
   • Identification of opportunities for increased statistical and operational efficiency
   • Discussion of simulation and other evaluation methods for determining the operating characteristics of proposed designs

3.00 Networking break

3.30 Logistical and Implementation Considerations
   • Discussion of logistical challenges and implementation methods for multicentre trials incorporating the adaptive approaches discussed in the workshop
   • Discussion of experiences (both successful experiences and adverse experiences) associated with the implementation of adaptive clinical trials

4.30 Oversight and Monitoring of an Adaptive Trial
   • Approaches to the oversight and monitoring of adaptive clinical trials
   • Considerations in the formation of Data and Safety Monitoring Boards (DSMBs) and their operation
   • Methods to ensure ongoing trial integrity and the acceptability of final trial results to regulators

5.00 End of workshop

About the workshop host
Roger J. Lewis, MD, PhD received his PhD in Biophysics in 1986 and his MD in 1987 from Stanford University. He completed clinical training in emergency medicine in 1990 and is currently a Professor at the David Geffen School of Medicine at UCLA and Chair of the Department of Emergency Medicine at Harbor-UCLA Medical Center. Dr. Lewis is a member of the Board of Directors for the Society for Clinical Trials. He is also the Senior Medical Scientist at Berry Consultants, LLC, a statistical consulting group that specializes in the design and implementation of adaptive clinical trials.
**ADAPTIVE DESIGNS IN CLINICAL TRIALS**

**Conference:** Monday 24th and Tuesday 25th March 2014, Holiday Inn Regents Park, London, UK  
**Workshops:** Wednesday 26th March 2014, London

**4 WAYS TO REGISTER**

**FAX** your booking form to +44 (0) 870 9090 712  
**PHONE** on +44 (0) 870 9090 711

**www.adaptivedesigns.co.uk**

**POST** your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

---

**DELEGATE DETAILS**

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.  

<table>
<thead>
<tr>
<th>Title</th>
<th>Forename</th>
<th>Surname</th>
<th>Address (if different from above)</th>
<th>Town/City</th>
<th>Post/Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

**ACCOUNTS DEPT**

<table>
<thead>
<tr>
<th>Title</th>
<th>Forename</th>
<th>Surname</th>
<th>Address (if different from above)</th>
<th>Town/City</th>
<th>Post/Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

---

**PAYMENT**

- **Cheque**  
- **Credit Card**  
- **UK BACS**  
- **Wire Transfer**

**TERMS AND CONDITIONS OF BOOKING**

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-100 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

- **UK BACS**  
- **Wire Transfer**

---

**MOBILE: 0870 881 0000**  
**FAX: 0870 881 0033**  
**EMAIL: bookings@smi-online.co.uk**

---

**VENUE** Holiday Inn Regents Park, Carburton Street, London, W1W 8EE

**EVENING BIRD**

- **Book by 29th November to receive £300 off the conference price**
- **Book by 31st January to receive £100 off the conference price**

---

**CONFERENCE PRICES**

<table>
<thead>
<tr>
<th>Fee</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMMERCIAl ORGANISATIONS</td>
<td></td>
</tr>
<tr>
<td>Conference &amp; 2 Workshops</td>
<td>£2697.00 + VAT £3236.40</td>
</tr>
<tr>
<td>Conference &amp; 1 Workshop</td>
<td>£2098.00 + VAT £2517.60</td>
</tr>
<tr>
<td>Conference only</td>
<td>£1499.00 + VAT £1798.80</td>
</tr>
<tr>
<td>Two workshops only</td>
<td>£1198.00 + VAT £1437.60</td>
</tr>
<tr>
<td>One workshop only</td>
<td>£599.00 + VAT £718.80</td>
</tr>
</tbody>
</table>

---

**LIVE STREAMING/ON DEMAND/ DOCUMENTATION**

<table>
<thead>
<tr>
<th>Price</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live Streaming</td>
<td>£999.00 + VAT (UK) £1198.80</td>
</tr>
<tr>
<td>On demand (available 24 hours after the event)</td>
<td>£599.00 + VAT (UK) £718.80</td>
</tr>
<tr>
<td>Access to the conference documentation on the Document Portal</td>
<td>£499.00 + VAT £598.80</td>
</tr>
<tr>
<td>The Conference Presentations - paper copy</td>
<td>£499.00 - £499.00</td>
</tr>
</tbody>
</table>

---

**DATA PROTECTION**

The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you instruct otherwise, we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasesmanager@smi-online.co.uk or visit our website www.smi-online.co.uk updates quoting the LHR as detailed above your address on the attached letter.